News

  • Apr 2020

    Coriell Institute Awarded $9.2M Biobanking Grant from National Institute of General Medical Sciences

    The Coriell Institute for Medical Research has been awarded a $9.2 million grant through an open competition from the National Institute of General Medical Sciences (NIGMS). This five-year award keeps Coriell in place as the steward of the NIGMS Human Genetic Cell Repository, a world-renowned collection of high quality cell lines and DNA samples representing genetic diseases, distinct human populations around the world, and more.

    read more

  • Mar 2020

    Coriell Institute for Medical Research Awarded $8.6 Million Biobanking Contract from National Institute on Aging

    The newly awarded $8.6 million funding keeps Coriell in place as the trusted steward of this collection and includes the addition of new innovative products to expand the collection. The NIA Aging Cell Repository was established at Coriell in 1974 and Coriell has continuously managed this unique resource ever since.

    read more

  • Feb 2020

    Coriell Researchers Identify SNP Associated with Obesity Risk

    Coriell researchers have found a new genetic indicator of obesity risk and bolstered the understood importance of one gene’s role in obesity risk. Their findings were published this month in Military Medicine.

    read more

  • Feb 2020

    Allen Institute for Cell Science Extends Agreement with Coriell Institute for Medical Research

    The Allen Institute has extended its contract with the Coriell Institute for Medical Research for the storage and distribution of its Allen Cell Collection, a cutting-edge collection of gene-edited human induced pluripotent stem cell lines. This collection was launched in 2016 with five cell lines, and since has grown to include more than 40 lines. The new agreement will continue this relationship for an additional three years.

    read more

  • Dec 2019

    Coriell Institute for Medical Research Scientist Receives Grant to Find Drivers of Breast Cancer

    Shoghag Panjarian, PhD, a research scientist at the Coriell Institute for Medical Research, has been awarded a grant from the W. W. Smith Charitable Trust to support her search for epigenetic factors that contribute to the development and growth of breast cancer.

    read more

  • Nov 2019

    Samples from The 90+ Study Added to NIA Aging Cell Repository

    The samples – a total of 351 lymphoblastoid cell lines – are associated with a long-term study of aging known as The 90+ Study. The 90+ Study is administered by a team of scientists from the University of California Irvine and its goal is to investigate the basic lifestyle and biological factors which underlie advanced aging.

    read more

  • Nov 2019

    NINDS Awards Coriell Institute for Medical Research $7.7 Million Contract

    The five-year award will support the NINDS Human Genetics Resource Center, a collection of biological samples and corresponding demographic, clinical, and genetic data made available to qualified researchers around the world. This repository includes samples from subjects with various diseases – such as cerebrovascular disease, dystonia, epilepsy, motor neuron disease, parkinsonism, and Tourette Syndrome.

    read more

  • Nov 2019

    New Stem Cell Lines Added to Aging Cell Repository

    A pair of new induced pluripotent stem cell lines has been added to the Aging Cell Repository, a collection of biomaterials sponsored by the National Institute on Aging (NIA).

    read more

  • Sep 2019

    NIH Funds New Centers to Expand, Diversify the Human Reference Genome

    The Coriell Institute for Medical Research will support one of the two new centers tasked with generating new reference sequences of the human genome.

    read more

  • Sep 2019

    Predictors of Response to Guadecitabine Found in Relapsed/Refractory AML Patients

    Patients with acute myeloid leukemia (AML), a leukemia which arises from bone marrow tissue, often see remission following their initial treatment, but for patients whose cancer returns, there are few options. One such option is guadecitabine, a novel DNA hypomethylating drug which slows problematic changes to a person’s epigenetic profile, but the drug is ineffective in a select number of relapsed or refractory AML patients and there has not been a way to determine who stands to benefit and who does not.

    read more